Company Overview and News
Castle Minerals Ltd's (ASX:CDT) recent reconnaissance work at its newly acquired Beasley Creek Gold Project in the Pilbara region has surpassed its expectations.
An orientation visit by Castle Minerals at the Coolyia Creek project’s Mt Roe and Hardey conglomerates in Western Australia has confirmed extensive gold mineralisation that is “more widespread than expected”, according to the company’s managing director.
Castle Minerals Limited (ASX:CDT) has secured the right to acquire an 80% interest in an exploration licence prospective for conglomerate hosted gold at Beasley Creek in the West Pilbara region.
Castle Minerals Ltd (ASX:CDT) shares touched $0.07 on Friday, a meteoric rise from its valuation of just over $0.01 a month ago.
Castle Minerals Limited (ASX:CDT) has raised $1,225,000 via a placement of shares at $0.035 each in which Artemis Resources (ASX:ARV) participated and will now hold a 4.8% stake in Castle.
Castle Minerals Ltd (ASX:CDT) has been the stand-out performer on the ASX during October, with its shares jumping over 300% to close on Friday at $0.045.
Castle Minerals Ltd (ASX:CDT) has gained another 36.1% to $0.049 in morning trade, with 24 million shares changing hands.
Castle Minerals Ltd (ASX:CDT) is dialled into one of the hottest exploration post codes in Australia, the Pilbara in Western Australia.
Azumah Resources Ltd (ASX:AZM) has received mid-program results grading up to 28.9 g/t gold from its multi-target drilling at the Wa Gold Project located in Ghana.
VANCOUVER, BC / ACCESSWIRE / July 20, 2016 / Castle Peak Mining Ltd. (TSXV: CAP) ("Castle Peak" or the "Company"), is pleased to announce that in preparation of drilling, a field crew is being mobilized to our priority prospects at the Akorade Project located in the southern Ashanti Belt, Ghana to:
Goldcrest Resources plc advises that the conditional sale and purchase agreement between Castle Minerals Limited (“Castle”) and Goldcrest for the acquisition of the Akoko prospecting license has been automatically terminated.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...